



# Press Release

**For immediate release**

May 29, 2009

## **CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1) 'Swine Flu' Vaccine**

CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, welcomes the Rudd Government's recent announcement of its intention to place an order to supply 10 million Australians with a vaccine against Novel Influenza A (H1N1) or 'swine flu'.

CSL is well-placed to meet the needs of the Australian population in responding to the current epidemic. CSL will prepare candidate vaccine for use in clinical trials to determine the formulation and dosage of the vaccine. The first batches are expected to be manufactured by late July/ early August. The Australian government will determine how the vaccine will be deployed.

In addition, as part of the global response to the novel influenza outbreak, CSL Biotherapies has reached an agreement with the US Government to provide it with influenza vaccine antigen in bulk form. The vaccine will also be manufactured at CSL's Parkville facility and will support the pre-pandemic influenza preparation efforts in the US.

"CSL has made a considerable investment in manufacturing facilities over the past few years and we now have one of the largest and most modern manufacturing facilities in the world. Established as a facility scaled for export, CSL provides Australia with more capacity per head of population than any other country globally. We are confident of being able to satisfy the needs of Australia and other countries in a timely way." General Manager of CSL Biotherapies Mary Sontrop said today.



# Press Release

---

Page 2

May 29, 2009

“CSL’s partnership with the Australian and US Governments to address the serious threat to public health that the A (H1N1) virus represents, is confirmation that we are a leader in the global influenza vaccines market,” she said. “In doing so, CSL will be applying more than 40 years of experience in developing and manufacturing influenza vaccines. “

**For more information about CSL Limited, visit [www.csl.com.au](http://www.csl.com.au)**

## **Media Contacts**

Australia and New Zealand

Dr Rachel David  
Director, Public Affairs  
CSL Limited  
Ph: +61 3 93891821  
[rachel.david@csl.com.au](mailto:rachel.david@csl.com.au)